

Anti-cancer discovery and development: Targeting the sweet tooth of cancer.

Monde Ntwasa

Department of Life & Consumer Sciences
University of South Africa
03 August 2017

1. Historical background
2. Current work
3. Future
4. Reflections

Cambridge University





Jesus College




Jesus College











“What forces drive such dramatic rearrangements in cells?”




Question: Molecular mechanisms that control Dorso-ventral axis determination

Drosophila – The fruitfly



For almost every organ in humans there is a match in flies, and common genes




Nobel Prize in Physiology or Medicine 1995
for discoveries around the genetic control of early embryonic development



Eric F. Wieschaus

"I will never forget the thrill of seeing cleavage and gastrulation for the first time in living frog embryos."




Edward B. Lewis

He generally avoided molecular explanations, for his observations, in part due to a feeling of humility towards most things biochemical, and in part from a suspicion that the available molecular mechanisms couldn't explain the complexity he saw in the flies.





Christiane Nüsslein-Volhard

"I immediately loved working with flies. They fascinated me, and followed me around in my dreams."



Christiane Nüsslein-Volhard



Toll

12 Maternal Effect Genes




Christiane Nüsslein-Volhard



“The genetic ordering of the Toll pathway is probably the thing that has had the biggest impact because of the importance of Toll-like receptors in mammalian immunity,” says Anderson.

Kathryn Anderson

Toll encodes a transmembrane protein and, together with its ligand, Spätzle, controls the entire dorsal-ventral pathway in *Drosophila* development. MAPS to position 97D on the left of chromosome 3.



Nature Reviews | Immunology

Research project:
Molecular mechanisms for Dorso-ventral axis determination – The cloning and heterologous expression of the Toll receptor

Research project:
Molecular mechanisms
for Dorso-ventral axis
determination – The
cloning and heterologous
expression of the Toll
receptor

Screening:
(i)genomic libraries
(ii)expression libraries



2 plausible clones



Sequencing

LRR47



Regular paper

Sequence and expression of LRR47, a novel embryonic leucine rich repeat protein of *Drosophila*

Makrli Nivonia, Beati G, S, C, Bachmann, Nicholas J, Galy

Show more

[https://doi.org/10.1016/0167-4781\(94\)00005-6](https://doi.org/10.1016/0167-4781(94)00005-6)

Get rights and content

Abstract

Leucine-rich repeats (LRRs) are 22–28 amino acid long sequence motifs found in a variety of extracellular, membrane and cytoplasmic proteins. They are believed to mediate specific protein-protein interactions and to function in cellular adhesion. In *Drosophila*, four LRR proteins are known and each plays an important role in embryogenesis. In this paper we report the cloning of a cDNA that encodes a fifth *Drosophila* embryonic LRR protein, LRR47. The sequence includes a hydrophobic N-terminal which may constitute an ER signal sequence, eight LRR copies and a unique C-terminal. The transcript of the LRR47 gene is detected in adult females and in early embryogenesis. It is not found in adult males and is only present at low levels in embryos after 6 h of development. In Western blot experiments, a protein of approx. 47 kDa, which is expressed in a similar developmental profile and purifies in peripheral membrane protein extracts, is detected by an antibody specific for LRR47. The LRR47 gene maps to position 32A on the left arm of chromosome 2, an interval in which three genes with semi-lethal maternal effects (*dal*, *hup* and *wal*) are located.

Recommended articles

Citing articles

Cloning of the Toll gene by screening gene libraries and isolated 2 clones

LRR47

- 47kDa protein with leucine-rich repeats
- Present in adult females
- Also during embryogenesis
- MAPS to position 32A on the left of chromosome 2

N-myristoyltransferase (NMT)

Journal of Cell Science

[Home](#) [Articles](#) [About us](#) [For authors](#) [Journal info](#) [Contact](#)

JOURNAL ARTICLES

Sequence and expression of *Drosophila* myristoyl-CoA: protein N-myristoyl transferase: evidence for proteolytic processing and membrane localisation

M. Nwossa, M. Egerton, N.J. Day
Journal of Cell Science 1997 110: 149-156

[Article](#) [Info & metrics](#)

 PDF

Summary

The enzyme N-myristoyl transferase transfers the 14 carbon fatty acid myristate to an N-terminal glycine residue in a small subset of cytoplasmic proteins. Many myristoyl proteins are components of cellular signalling pathways, some of which play important roles during embryonic development, for example protein kinase A. Thus, the function of N-myristoyl transferase is probably essential for embryogenesis and it is of some interest to study the enzyme in an organism with well understood developmental biology. In this paper we report the purification of a processed form of the *Drosophila* enzyme from peripheral membrane fractions of embryos by affinity chromatography to a protein

N-Myristoyltransferase (NMT)

- Essential for embryogenesis
- Catalyses lipid modification of proteins

Cape Town – Welcome Trust Fellowship



Cape Town – Welcome Trust Fellowship



Jasper Rees



Cape Town



The New Gene

- Identified an interesting gene in Chinese hamster ovary (CHO) cells using promoter trap mutagenesis to screen for genes involved in programmed cell death (apoptosis).

Cape Town – Welcome Trust Fellowship



Jasper Rees



Sonti Apies



Cape Town – Welcome Trust Fellowship

Departure from
Cape Town



Sonti Apies



Johannesburg



Johannesburg



(i) NMT work continues



Sonti Apies



Arshad Mather

Characterization of the new gene

N-myristoyltransferase



Experimental Cell Research

Volume 262, Issue 2, 10 January 2007, Pages 134-144



Original Article

Drosophila Embryos Lacking N-Myristoyltransferase Have Multiple Developmental Defects

Monde Nkavwe¹, Scott Aageson¹, David A. Schaffhausen¹, Nicholas J. Gay^{1,*}



Show more

<https://doi.org/10.1006/exr.2000.6036>


Get rights and content

Abstract

Lipid modification of proteins by the addition of myristic acid to the N-terminal is important in a number of critical cellular processes, for example, signal transduction and the modulation of membrane association by myristoyl switches. Myristic acid is added to proteins by the enzyme N-myristoyltransferase (NMT) and in this paper we detail the effects on embryonic development of a null mutation in the *Drosophila* *NMT* gene. Mutant embryos display a range of phenotypes, including failures of head involution, dorsal closure, and germ-band retraction, morphogenetic processes that require cellular movements. Embryos with milder phenotypes have more specific defects in the central nervous system, including thinning of the ventral nerve chord and, in some embryos, specific scission at parasegment 10. Staining of mutant embryos with phalloidin shows that the mutant embryos have a disrupted actin cytoskeleton and abnormal cell morphology. These phenotypes are strikingly similar to those caused by genes involved in dynamic rearrangement of the actin cytoskeleton. For example the myristoylated nonreceptor tyrosine kinases Darc42A and Darc64B were shown recently to be key regulators of dorsal closure. In addition, analysis of cell death reveals widespread ectopic apoptosis. Our findings are consistent with the hypothesis that the myristoyl switches



The New Gene



- Tumour suppressors
- Play critical roles in the cell cycle

SNAMA probably plays an anti-apoptotic function



Available online at www.sciencedirect.com

SCIENCE @ DIRECT[®]

Journal of Invertebrate Biology 177 (2008) 140–154



<http://www.elsevier.com/locate/jinb>

SNAMA, a novel protein with a DWNN domain and a RING finger-like motif: A possible role in apoptosis

Arshad Mather, Mpho Rukgomez, Monde Ntwana^{*}

School of Molecular and Cell Biology, University of the Witwatersrand, 205 210, South Africa


Received 1 February 2008; received in revised form 14 October 2008; accepted 11 January 2009

Available online 28 January 2009

Abstract

We have characterized SNAMA a hitherto uncharacterized *Drosophila* protein that appears to play a role in apoptosis. SNAMA (something that sticks like glue) is a 1231 amino acid protein with a conserved 76 residue N-terminal domain called Domain With No Name (DWNN). The DWNN domain was first identified in *cytotoxic T Cell-resistant* (CTR) cells using promoter trap mutagenesis to screen for genes involved in apoptosis. Subsequently, this domain was identified in other eukaryotic organisms including animals and plants. The SNAMA homologs to abundant early in embryogenesis but reduced in other embryonic and in adult nuclei and females. Human and mouse homologues of SNAMA are known to bind to p53 and to the transcription factor IRF1 suggesting a role in transcriptional regulation and cell cycle control. We took advantage of a P-element insertion line in which the P-element is inserted in the first exon, to investigate the biological function of the gene. These mutants are lethal when homozygous. Apoptosis appears early during embryogenesis and is observed ventrally throughout the germline. The DWNN domain has a ubiquitin-like fold and may interact with a subset of cellular proteins. There is also a conserved RING finger-like motif along the sequence of SNAMA following a CTRC zinc finger.

© 2009 Elsevier B.V. All rights reserved.



Cells lacking SNAMA commit suicide

Article

The *Drosophila* Retinoblastoma Binding Protein 6 Family Member Has Two Isoforms and Is Potentially Involved in Embryonic Patterning

Rodney Hull ¹, Brent Oosthuysen ¹, Umar-Faruq Cajee ¹, Lehlogonolo Mokoghoa ¹,
 Elcenc Nweke ¹, Ricardo Jorge Antunes ¹, Theresa H. T. Coetzer ² and Monde Ntwasa ^{1,*}

- Two isoforms – SNAMA A & B
- Differential expression
 - Spatial
 - Temporal
- Expressed in pole cells





Figure 2. Differential expression of SNAMA during oogenesis and embryogenesis. (A) Schematic representation of the Snama genomic organization showing the exon-intron structure of Snama A and B transcripts. (B) Domain structure of SNAMA A and B


Human RBBP6 – and *Drosophila* SNAMA




- Ubiquitin-like domain called DWNN – Domain With No Name
- Zinc finger – C2HC
- RING finger like motif – probably with E3 ligase activity
- Proline-rich region
- Lysine-rich region
- RS-region
- coiled-coil
- p53 – binding domain (downstream the RING finger)
- pRB – binding domain (also downstream the RING finger)

Is SNAMA (RBBP6) involved in p53 signaling?



Humans



Fruitfly



Is SNAMA (RBBP6) involved in p53 signaling?



- Flies were challenged with camptothecin
- Proteomic analysis during and after treatment

Is SNAMA (RBBP6) involved in p53 signaling?

ANTI-CANCER DRUGS

Articles & Issues

For Authors

Journal Info

Log in to view full text. If you're not a subscriber, you can:

[Buy This Article >](#)

[Become a Subscriber >](#)

[Request Permissions >](#)

Ovid[®]

Institutional members
access full text with
OVID[®]

« Previous issue | Next issue »

Glycolytic flux occurs in *Drosophila melanogaster* recovering from camptothecin treatment

Hui, Rodney; Miyata, Monda; McMillan

Anti-Cancer Drugs, November 2010 - Volume 21 - issue 10 - pp 945-957

doi: 10.1087/CAD.0b013e3180333e2860


Peer-Review Reports

Full



Abstract

Author Information

Camptothecin (CPT) and CPT-derived drugs are widely used against gynaecological and colorectal cancers. On account of their mechanism of action these drugs target rapidly dividing cells and may have an adverse effect on normal tissues. We sought to investigate their impact on normal cells by using *Drosophila* as a model. We investigated the possible involvement of *Drosophila* homologue of p53 (Dmp53) and a member of the retinoblastoma binding protein II family, known as Snama. On account of its molecular features and experimental evidence gleaned from mammalian studies we propose Snama as a candidate in Dmp53 regulation. We have



Is SNAMA (RBBP6) involved in p53 signaling?



- DMSO
- Untreated
- Camptothecin

- *Dmp53* increases following camptothecin treatment
- *SNAMA* decreases following camptothecin treatment

Otto Warburg




In the 1920s Otto Warburg found that, under aerobic conditions, tumour tissues metabolize approximately tenfold more glucose to lactate in a given time than normal tissues, a phenomenon known as the Warburg effect.



Sidney Weinhouse (1976). “I feel that as our perspectives have broadened over the years, the burning issues of glycolysis and respiration in cancer now flicker only dimly; they have receded in importance, and are no longer in the mainstream of cancer research”.


The Warburg Effect is a widespread cancer-associated trait. It is exploited as a diagnostic e.g. positron emission tomography (PET) whereby 18-fluorodeoxyglucose (FDG), preferentially accumulates in tumour cells as a result of their rapid uptake of glucose. Because of the prevalence of this phenotype, PET is an effective clinical imaging technique to detect most cancers and monitor therapeutic responses.

Positron Emission Tomography (PET)




p53 controls glucose metabolism at multiple points


Negative regulators: MDM2 and RBP6



p53 controls glucose metabolism at multiple points




Negative regulators: MDM2 and RBBP6




Exogenous pyruvate

Would by-pass of the glycolytic pathway selectively protect normal cells during chemotherapy?


Methyl pyruvate





Irinotecan




Normal Lung fibroblast cell line






Lung cancer cell line









- Methyl pyruvate protects a MRC-5 lung fibroblasts from irinotecan-induced cell death
- Methyl pyruvate accelerates the death of cancer lung fibroblasts




Affected Biological processes - GENMANIA




- upregulated in the MRC-5 lung fibroblasts promote angiogenesis, cell cycle regulation, cell survival and control glucose metabolism.
- upregulated genes in A549 fibroblasts mediate apoptosis






A549:
upregulated genes

- telomere maintenance via telomerase
- intrinsic apoptotic signalling pathway
- vascular endothelial growth factor receptor signalling pathway
- positive regulation of endothelial cell proliferation
- programmed necrotic cell death
- positive regulation of protein ubiquitination
- nucleotide excision repair, (dna damage removal)
- regulation of endothelial cell proliferation
- metabolism proteins



A549:
Downregulated genes

- Angiogenesis
- DNA polymerase activity
- Mitosis
- Myeloid cell homeostasis



MRC-5:
upregulated genes

- Angiogenesis
- Cellular response to hypoxia
- Regulation of insulin-like growth factor receptor signalling pathway
- Positive regulation of cell adhesion
- Regulation of DNA replication
- Regulation of extrinsic apoptotic signalling pathway

- methyl pyruvate directly triggers opposite outcomes in these cells: pro-angiogenic and pro-survival factors in the MRC-5 fibroblasts and anti-angiogenic and apoptotic factors in fibroblasts.

Key observations

- methyl pyruvate protects irinotecan-treated normal lung fibroblast cell line (MRC-5) probably by turning off the **p53/p21 axis** of the apoptotic pathways.
- When the MRC-5 fibroblasts recover in drug-free medium, the **intrinsic apoptotic pathway** is also turned off
- In contrast, the **mere introduction of exogenous pyruvate kills the cancer lung fibroblasts (A549)**.
- When combined with irinotecan cell death occurs in cancer cells but not in the normal cell line.



**Methyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death:
Potential use as adjunctive to chemotherapy**

Bernice Monchusi¹ and Monde Ntwasa^{2*}

Food for thought

- **Sugar feeds cancer**
- **Carbohydrate diet may no longer be overlooked during the management of cancer**
- **Problem – carbohydrates are required by all cells**
- **Bypassing glycolysis and boosting respiration may be a good strategy to protect normal cells during chemotherapy and in the management of cancer in general.**



“Poor carbohydrate diet supports therapy with amatin.”



Cell
Science & Therapy

Volume 4 Issue 10 Year 2012, 4-13
http://dx.doi.org/10.4171/2012-1010

Review Article

Open Access

Tumor Therapy with *Amanita phalloides*: Remission of a Tumor Disease and Dietary Effect of Sugar

Isolde Riede*

Independent Cancer Research, Im Arden 7, D-60562 Ullersheim, Germany

Abstract

Molecular events that cause tumor formation upregulate a number of HOX genes, called switch genes, encoding for RNApolymeraseII transcription factors. Thus, RNApolymeraseII is used to full extent in tumor cells but not in somatic cells. *Amanita phalloides* contains amanitin, inhibiting RNApolymeraseII. Application of *Amanita phalloides* influences tumor cell (but not normal cell) activity. Dilutions of *Amanita phalloides* are applied to a patient with both, colon carcinoma and thyroid carcinoma. Monitoring tumormarkers, different doses of *Amanita* are applied. After two years of stabilization, somatic investigations and imaging methods reveal complete remission. Change of dietary practice with the addition of daily 70 gram sugar lead to increase of tumormarker values. Following dietary without sugar and reduced carbohydrates decrease tumormarker values. With sugar, tumor activity increase despite *Amanita* tumor therapy, therefore, poor carbohydrate diet supports the therapy.

RESEARCH ARTICLE

Ethyl Pyruvate Combats Human Leukemia Cells but Spares Normal Blood Cells

Gerd Birkenmeier^{1*}, Nasr Y. A. Hemdan^{1*}, Susanne Kurz¹, Marina Bigl¹, Philipp Pioner^{1,2,3,4}, Tewodros Debebe^{2,4}, Martin Buchold¹, Rene Thieme⁵, Gunnar Wichmann⁶, Faramarz Dehghani⁷

2016

RADIATION RESEARCH **168**, 552–559 (2007)
 DOI:10.1186/1547-7732-168-552
 © 2007 by Radiation Research Society.
 All rights of reproduction in any form reserved.

Ethyl Pyruvate, a Potentially Effective Mitigator of Damage after Total-Body Irradiation

Michael Epperly,^a ShunQian Jin,^a Suhua Nie,^a Shaoman Cao,^a Xichen Zhang,^a Darcy Franicola,^a Hong Wang,^a Mitchell P. Fink^{b,c,d} and Joel S. Greenberger^a

Departments of ^a Radiation Oncology, ^b Critical Care Medicine, ^c Surgery and ^d Pharmacology, University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213


The Future

Eureka



The Future

Is RBBP6 drugable?



pRB-binding domain

p53-binding domain



Pugh et.al; BMC: 2006


Kappo et.al; JBC VOL. 287, NO. 10, pp. 7146–7158, March 2, 2012

The Future

3-D structure





Putative Binding sites



Molecular docking & drug discovery




RING domain




Is RBBP6 drugable?

p53BD



The Future


The field of cancer has largely been guided by a reductionist focus on cancer cells



Design, construction and testing of a micro-system to simulate the tumor microenvironment.


The Future

Metabolic reprogramming and the immune system



Ntombi and Phil

How LPS promotes Warburg metabolism in macrophages and Dendritic cells



(Kelly et al. 2005).

Future



Biomarkers for early Diagnosis of Pancreatic cancer.

- Validation of pyruvate esters as adjunctive to chemotherapy
- Development of drug leads



Acknowledgements



Prof Eugene Dowdle
(Cape Town)



Nick (Cambridge, UK)



Jean-Marc
(Strasbourg, France)



Shoichiro
(Tohoku, Sendai)



Hazel (MIT, USA)

Professor
Emeritus
Barry
Fabian



Jean Marc
and Friends

Best Friends



Flylab people



Acknowledgements



- Canon Collins Educational Trust of South Africa

- The Royal Society (UK)

OPENHEIMER
MEMORIAL
TRUST

Carnegie Corporation
of New York



European
Molecular
Biology
Organization

- Cambridge Commonwealth Trust.
- Dr Rooha Variava

Thank you